a p p l i c at i o n N o t e

Pre-clinical Imaging
AuthorJeffrey D. Peterson, Ph.D.
PerkinElmer, Inc.
Waltham, MA USA

Comparison of PerkinElmer
Vascular Pre-clinicalFluorescent Imaging
Agents in Oncology andInflammation Research

Abstract

Optical-based in vivo imaging of blood vessels and vascularleak is an emerging modality for studying changes that
occur in a variety of different cancers and inflammatory
states. A number of fluorescent imaging agents that circulate
with the blood, but have no target selectivity, have beenused to detect tumor leakiness as an indication of abnormal
tumor vasculature. Inflammation is also characterized
by distinct vascular changes, including vasodilation andincreased vascular permeability, which are induced by theactions of various inflammatory mediators. This process isessential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites inneed of healing or protection from infection.

Imaging agents that fluoresce in the near infrared (NIR) are particularly useful for detection ofchanges in vascular permeability because of relatively low tissue absorbance, permitting effective
penetration into deep tissue sites. NIR vascular agents can vary in size and physicochemical properties that affect their overall utility for particular imaging applications or affect the time window
for optimal imaging. In these studies, we compared three NIR fluorescent agents, Superhance™
(a low molecular weight agent), AngioSense® (a high molecular weight agent), and AngioSPARK®
(30-50 nm nanoparticles). Each agent differs significantly in pharmacokinetics, biodistribution,and tissue clearance rates, offering three slightly different imaging tools for cancer and inflammation research. All three agents can detect tumor vascular leak, with AngioSense showing
superior signal to background in orthotopic mouse breast cancer. In contrast, Superhance shows
superior imaging capability when applied to a mouse model of acute, inflammatory paw edema.
AngioSPARK, designed as a highly robust agent for intravital microscopy assessment of vesselmorphometry, shows the ability to image both tumors and inflammation with long term accumulation at the imaging site (sometimes a benefit for time course studies). Images and quantitationof timecourses in animal models of cancer and inflammation provide guidance regarding optimal
usage of these three vascular imaging agents.

Materials and methods
Fluorescent Agents for the Detection of Cancer andInflammation
A variety of non-targeted fluorescent agents (Superhance,
AngioSense, and AngioSPARK) were used as vascular agentsto image fluorescent signal circulating through tissues, bloodleakage and accumulation into tumors, and extravasationof agents during edema. The imaging doses were as recommended in the product inserts, but all data was normalized
to reflect a 2 nmol per mouse intravenous dose for easiercomparison.

As nu/nu mice have no hair, depilation was not required fortumor studies. Tumor-bearing mice were imaged using the
FMT® 2500 Quantitative Pre-clinical Imaging System whichcollected both 2D surface images as well as 3D tomographic
imaging data. Paws from carrageenan edema mice wereimaged without the requirement for hair removal. Paws
were imaged after careful position of mice on an indexmatching imaging block.
FMT reconstruction and analysis

Eight week-old female nu/nu mice were injected in both
upper mammary fat pads with 0.5x106 4T1 mouse breast
adenocarcinoma cells per site. 5-7 days later, mice were
injected with vascular agents and imaged (at indicatedtimes) using FMT to detect and quantitate levels of fluorescence throughout the body, including tumor sites, control
sites, and different organ systems.

The collected fluorescence data was reconstructed by FMT
2500 system software (TrueQuant™) for the quantitationof three-dimensional fluorescence signal within tumors or
inflamed paws. Three-dimensional regions of interest (ROI)
boxes were drawn to encompass the relevant biology (i.e.
tumors or hind paws). Control ROIs were placed to capture
a control site, either a flank region for tumor mice or contralateral paws for CG mice. The software determined thetotal pmoles of fluorescence within each 3D ROI. Additional
ROIs placed to encompass the heart region provided usefulquantitation regarding blood pharmacokinetics.

Carrageenan Paw Edema Model

Introduction

BALB/c mice were injected in the right hind footpad with
30 µL of a carrageenan (CG) solution in PBS (0.125-1%).
The left hind footpad was injected with 30 µL PBS andserved as an internal control. Paw edema was determinedusing a spring-loaded caliper to measure paw thickness ascompared to controls. Injection of 2 nmoles/mouse of various
NIR vascular agents to enable quantitative biological imaging
readouts.

Vascular Agents

4T1 Syngeneic Tumor Model

In vivo FMT 2500 tomographic imaging
Mice were anesthetized by isoflurane inhalation. For micewith hair, depilatory lotion (Nair® Church & Dwight Co.,
Inc., Princeton, NJ) is applied thickly on skin over the upper
torso (front, back, and sides) of each mouse, rinsed off withwarm water, and re-applied until all hair has been removed.

Imaging has become a crucial tool in a variety of therapeuticareas in disease research, from preclinical to clinical studies.
Historically, anatomical modalities of imaging (e.g. MRI, CT)
have paved the way, providing valuable information used in
the diagnosis of many diseases, offering quantitative information regarding dimensional changes in important biology
such as tumor size and location, joint space narrowing, etc.
As alterations in blood flow or oxygenation underlie diseaseat the tissue or cellular level, physiological processes such as
blood flow and perfusion have also become very important.
Increased tumor vascular permeability can be an early indicatorof tumor angiogenesis, tumor progression, and poor

Table 1. Basic properties of four different PerkinElmer vascular pre-clinical fluorescent imaging agents.
Superhance

AngioSense

AngioSPARKAgent type

Albumin-binding small molecule

PEGylated large scaffold

Nanoparticle

Molecular weight or size

1540 g/mol

250,000 g/mol

30-50 nm particles

Ex/Em

675/692 nm

680/700 nm

673/690 nm

Blood half-life

1.5 h

7h

20 h

Tissue half-life

5h

72 h

> 100 hAgent Summary. Characteristics of the agents (MW/size, excitation/emission [Ex/Em], and blood/tissue pharmacokinetics) were determined in multiple
independent studies. Blood half-lives were measured by blood collection from mice at different times post-intravenous injection. Blood samples were measured
for fluorescence levels in a fluorescence microplate reader. Tissue half-lives were determined by time course FMT 2500 imaging of tumors.

2therapeutic outcome. In inflammatory diseases andconditions, increased vascular permeability is an indicationof alterations in fluid homeostasis, either as an acuteedema response or in serious, chronic organ conditions.
Radiotracers, chromium- or gadolinium-based paramagnetic
agents, and radio-opaque agents have often been used as
vascular contrast agents, however fluorescent-labeled agentsoffer a useful and safe alternative, particularly for preclinicalimaging. Agents as simple as fluorescent dyes have beenused to visualize tumors, achieving contrast enhancement
through enhanced permeability of tumor vessels andenlarged interstitial space. Typically, however, larger
fluorophore-labeled molecules are often chosen to better
extend plasma half-life and to mimic leak of plasma proteins(i.e. provide a relatively slow leakage rate).
In the current studies, three different near infrared
fluorescent contrast agents were assessed; Superhance 680,
AngioSense 680, and AngioSPARK 680 have different physicochemical compositions, different blood pharmacokinetics(Table 1), and show slightly different imaging uses.

Circulation levels of each agent were assessed non-invasively
by longitudinal imaging of the heart region at select time
points. Figure 1 shows the different circulating levels
detected and quantitated in living mice by FMT 2500,
measurements in close agreement with half-life values
in Table 1 determined by ex vivo blood assays.
Imaging Tumors with Vascular Agents
To determine the optimal imaging time points for thedifferent vascular imaging agents we used a syngeneic
mouse tumor model, orthotopic implantation of 4T1 mousebreast adenocarcima at two sites (in each upper mammary
fat pad). Although this model does not require deep tissue
imaging for detection, it provided an experimental approachthat permitted the comparison of FMT imaging and planar
imaging in the analysis of vascular agent kinetics. As shownin the diagram in Figure 2, tumors were allowed sufficient
time to grow prior to injection of imaging agents, after
which imaging datasets were acquired at different time
points to characterize the kinetics of tumor fluorescence
accumulation and tissue washout.

These agents were assessed for their ability to image tumor
vascular leak and acute carrageenan paw edema. Agentswere assessed by 3D fluorescence molecular tomographyand 2D planar imaging at a variety of time points after
injection into mice. The 3D imaging offered quantitative
detection throughout the tissue, whereas 2D imaging
provides a simple and rapid means of detecting surfaceweighted fluorescence (i.e. mostly the fluorescence in theouter mm of the tissue).

Imaging blood levels.
Imaging agents were
injected intravenously,
and anesthetized mice
were imaged by FMT at
5 minutes and 1, 3, 24,
48, 72, and 96 hours.
Fluorescence tomographic datasets wereanalyzed by placing three
dimensional ROIs in theheart region to quantitate
the fluorescence changes
over time in units of pmol.

Results
Vascular Agent Properties
Fluorescent vascular imaging agents can vary widely in
structure, size, and physiochemical properties (from small
molecule dyes to large nanoparticles), and these differences
can significantly affect their pharmacokinetics, biodistribution,and metabolic clearance characteristics. These properties
will further impact the types of biology that can be imaged
as well as the optimal imaging timepoints. In order toachieve an effective level of agent in the target tissues(i.e. sites of tumor vascularity, inflammation-based edema,or tumor-associated vascular leak) the agent will be imaged
in circulation immediately upon injection, and the circulatinglevels will drive the extravasation from circulating bloodto the tissue of interest, either accumulating in areas ofenhances vascular permeability or passively extravasating
into normal tissues. Table 1 shows the 3 different agents
examined in the present studies.

Figure 1. Blood levels of vascular agents.

4T1 Tumor Cell
Implantation

Vascular Agent(IV Injection)

5-10 days

In Vivo FMT
Imaging

0-96 hnu/nu mice

Figure 2. 4T1 orthotopic breast cancer model.

3

A. Whole body, 3h

B. Tumor region assessment

Imaging tumors. FMT and planar images show thepatterns of fluorescence that occur in animals bearing
tumor masses on the upper mammary fat pads.
A. Whole body signal by FMT imaging.
B. FMT imaging showing only tumor region
fluorescence over time. Inset panels represent surface
fluorescence detected by planar imaging.

Figure 3. Superhance tumor imaging.

Determining optimal tumor imaging timepoints forSuperhance
To determine the optimal imaging timepoint relative toagent injection, we imaged 4T1 tumor-bearing mice at
different times post-Superhance 680 injection (Figure 3).
Whole body images at 3 h post-injection (Figure 3A) reveal
signal throughout the body (including bladder, intestines,
liver, and heart) as well as in the tumor periphery.
Careful FMT assessment of the tumor regions at each of thetime points reveals high heart and carotid/jugular signal at
5 min post injection, interfering with proper FMT analysis oftumors. The maximal signal over background (Figure 4) was
seen with FMT at 3 h, with signal distributed throughout thetumors at all time points rather than localizing only in thetumor margins or periphery. Both FMT and planar imaging
can detect differences as compared to control sites, but

A. FMT Quantitation

planar imaging faces difficult background signal due to highskin levels. FMT would offer the additional advantage of thedetection of deep tissue tumors undetectable at the surface
by 2D planar imaging.

Superhance Comments:
1. Agent provides good tumor definition by planar
imaging at 3-24 h. FMT shows heterogeneous signal
throughout the tumor region.
2. Earliest time (5 min) in the tumor region is mostly
attributed to skin/heart/carotid signal.
3. Fluorescence distribution pattern indicates accumulation
throughout the tumor rather than just at tumor margins,suggesting efficient tumor penetration.

B. Planar Assessment

Fluorescence (pmol)

Superhance quantitation.
Fluorescence within tumor
regions as well as control and skinsites were determined by A. FMT
imaging, and B. planar imaging
analysis. All fluorescencequantitation in control sites isadjusted to match the volume(FMT) or area (planar) capturedby the tumor site analysis.

Time Post-Injection (h)Figure 4. Superhance tumor fluorescence quantitation.

4

Time Post-Injection (h)A. Whole body, 24h

B. Tumor region assessment

Imaging tumors. FMT and planar images show thepatterns of fluorescence that occur in animals bearing
tumor masses on the upper mammary fat pads.
A. Whole body signal by FMT imaging.
B. FMT imaging showing only tumor region
fluorescence over time. Inset panels represent surface
fluorescence detected by planar imaging.

Figure 5. AngioSense tumor imaging.

Determining optimal tumor imaging timepoints for
AngioSense
To determine the optimal imaging time point relative to agent
injection, we imaged 4T1 tumor-bearing mice at different
times post-AngioSense 680 injection (Figure 5). Wholebody images at 24 h post-injection (Figure 5A) reveal signal
throughout the body (including bladder, intestines, liver,and heart) as well as in the tumor periphery.
Careful FMT assessment of the tumor regions (Figure 6)
showed a mostly vascular signal from 5 minutes to 3 h. The
maximal tumor signal over background was seen at 24-48 h,with signal distributed throughout the tumors at 24-48 h.
At later time points (72-96 h) signal appears to clear fromthe center of the tumors and localizes in the tumor margins.

A. FMT Quantitation

Both FMT and planar imaging can detect differences as compared to control sites, although multiple studies have shown
detection of deep tissue tumors with AngioSense that are
not detectable by 2D imaging.

AngioSense Comments:
1. For superficial tumors, 3D and 2D tumor datasets
generally align well.
2. Regions of low-grade background signal can bevisualized.
3. Maximal signal is at 24-48 h with clearance to themargins occurring at a steady rate thereafter.

B. Planar Assessment

Fluorescence (pmol)

AngioSense quantitation.
Fluorescence within tumor
regions as well as control and skinsites were determined by
A. FMT imaging, and B. planar
imaging analysis. All fluorescencequantitation in control sites isadjusted to match the volume(FMT) or area (planar) capturedby the tumor site analysis.

Time Post-Injection (h)Time Post-Injection (h)Figure 6. AngioSense tumor fluorescence quantitation.

5

A. Whole body, 3h

B. Tumor region assessment

Imaging tumors. FMT and planar images show thepatterns of fluorescence that occur in animals bearing
tumor masses on the upper mammary fat pads.
A. Whole body signal by FMT imaging.
B. FMT imaging showing only tumor region
fluorescence over time. Inset panels represent surface
fluorescence detected by planar imaging.

Figure 7. AngioSPARK tumor imaging.

Determining optimal tumor imaging timepoints for
AngioSPARKTo determine the optimal imaging time point relative toagent injection, we imaged 4T1 tumor-bearing mice at
different times post-AngioSPARK 680 injection (Figure 7).
Whole body images at 24h post-injection (Fig 7A) reveal
signal throughout the body (including bladder, intestines,
liver, and heart) as well as in the tumor.
Careful FMT assessment of the tumor regions (Figure 8)
showed a mostly vascular signal from 5 minutes to 3 h. The
maximal tumor signal over background was seen at 24 h,with signal distributed throughout the tumors at 24-48 h.
At later time points (72-96 h) signal appears to clear fromthe center of the tumors and localizes predominantly in the

A. FMT Quantitation

tumor margins. Both FMT and planar imaging can detect differences as compared to control sites. FMT would offer the
additional advantage of the detection of deep tissue tumors
undetectable at the surface by 2D planar imaging.

AngioSPARK Comments:
1. For superficial tumors, 3D and 2D tumor datasets
generally align well.
2. Regions of low-grade background signal can bevisualized.
3. Maximal signal is at 24-48 h with clearance to themargins occurring but little overall clearance prior to
96 h.

B. Planar Assessment

Fluorescence (pmol)

AngioSPARK quantitation.
Fluorescence within tumor
regions as well as control andskin sites were determined by
A. FMT imaging, and B. planar
imaging analysis. All
fluorescence quantitation incontrol sites is adjusted tomatch the volume (FMT) or
area (planar) captured by thetumor site analysis.

Time Post-Injection (h)Figure 8. AngioSPARK tumor fluorescence quantitation.

6

Time Post-Injection (h)Comparison of three vascular agents in oncology
imaging

It is interesting to note that AngioSense appears to provide
the optimal combination of pharmacokinetics and efficiency
in tumor accumulation, as shown by its ability to achieve thehighest levels of tumor signal. AngioSPARK shows greatly
extended blood pharmacokinetics, and because of its large
size it appears to be less efficient at accumulating withintumors. Its slow overall clearance from tissue, however,offers a method of long term tumor imaging. Superhance,
because of its very short circulation half-life shows the lowest
tumor signal, yet it provides a very early readout (3 h).
It is important to note that these three agents show noeffect on 4 day tumor growth (by direct physical measurement of tumor dimensions) as compared to tumors inanimals receiving no imaging agent injection (Figure 10).
This indicates that these agents are not altering tumor
biology by passively accumulating within the tissue.

Tumor FL - BKG (pmol)

Comparison of Tumor Imaging
Kinetics

Tumor size progression
is not affected by agent
injection. Tumor volume
calculated from caliper
measurements of length
and width from eachtumor over time showsthat tumors in all mousegroups grow at a comparable rate and to
approximately 2.5X
volume increase.

Tumor Growth (% of Control)

Superhance, AngioSense and AngioSPARK show clear differences in physicochemical properties, blood pharmacokinetics(Table 1, Figure 1) as well as in optimal imaging time points(indicated by arrows) and tissue clearance. All three agents
provide good tumor definition both by FMT and planar
imaging of these superficially-implanted tumors, and (whenusing FMT) deep tissue tumors can be detected as well.

Agents Do Not Affect Tumor GrowthTime Post-Injection (h)Figure 10. Effects on tumor progression.

Imaging acute edema with vascular agents
To determine the optimal imaging time points for thedifferent vascular imaging agents we used a mouse modelof acute neutrophil-driven paw edema induced by injectionof carrageenan (CG) into the right hindpaws (Figure 11).
This provided an experimental approach that permitted
the comparison of FMT imaging and planar imaging in theanalysis of vascular agent kinetics. Superhance was injected
at t = 2 h post carrageenan, whereas AngioSense andAngioSPARK were injected at t = 3 h, to accommodate thedifferences in blood pharmacokinetics and to permit imaging
at the peak edema response (3 h). As shown in Figure 12,
all three agents showed increased signal in carrageenan
paws, although AngioSPARK showed high backgroundsignal in control paws. Superhance cleared quickly fromtissue, making this agent ideal for imaging acute edema.
Both AngioSense and AngioSPARK showed continued
carrageenan paw accumulation at 24 h, a time at which
there is less edema and more cellular inflammation.
BALB/c miceTime Post-Injection (h)Tumor FL - BKG (pmol)

Comparison of Tumor Imaging
Kinetics

Carrageenan
footpad injection

Paw Tissue Histology(H&E Stain)

Vascular Agent

3h
Edema

21 h
Cellular
Inflammation

Swelling
Edema
C ellular Inflammation

Paw Inflammation Timecourse
Response

Time Post-Injection (h)Comparison of vascular
agents. Fluorescencewithin tumor regions(subtracting backgroundsignal) were determined
by A. FMT imaging, andB. planar imaging analysis.
All fluorescencequantitation in control
sites is adjusted to matchthe volume (FMT) or area(planar) captured by thetumor site analysis.

Figure 9. Vascular agent tumor imaging summary.

0

12

24
Time (h)36

48

Figure 11. Carrageenan Paw Edema (CPE)7

Imaging Acute Edema with vascular agents

A. FMT Imaging

3h

24 h

B. Planar Imaging

3h

24 h

Imaging Acute Paw Edema Induced by Carrageenan Injection. FMT and planar
images show the patterns of fluorescence of three different vascular imaging agentsthat accumulate in paws of animals with inflammatory edema induced in the rightfootpad.
A. Paw signal by FMT imaging. Numbers indicate quantitated pmol per paw.
B. Planar imaging of the same mice shows the superficial fluorescence associated withthe edema response.

Comparison of 3 h and 24 h imaging results (Figure 13A)
with paw swelling levels (measured by caliper) shown in
Figure 13B suggests that Superhance imaging provides good
detection and signal to noise at 3 h with excellent statisticalsignificance despite using only 3 mice per group. The
Superhance results agree well with the 3 h paw swelling
results, and signal washes out appreciably by 24 h. In contrast,
both AngioSense and AngioSPARK detected paw inflammation
best 24 h post-injection. Thus, for these two agents, although
they accumulate during the edema phase of the inflammation,
their signals are assessed during the cellular inflammation
phase. It is clear however, that Superhance (1 h post injection) is
ideal for assessing acute inflammatory edema, and the resultsfor individual paws correlate very well with paw thickness
measurements (Figure 13C). The other agents require imaging
long after the peak edema response and do not correlate aswell with peak edema paw thickness. Other studies in morechronic forms of cellular inflammation, such as arthritis, show
a strong benefit with AngioSense and AngioSPARK imaging(data not shown). Planar imaging was less sensitive than FMT
imaging at detecting differences between edema and control
paws, with significant interference by high reflectance background signal.

Figure 12. Carrageenan Paw Edema imaging.
A. FMT Paw Qantitation*
Paw FL (pmol)

B. Paw Thickness Changes
AngioSPARK#

3 h Paw Swelling
edema
**

*
Paw Thickness (mm)AngioSense

Superhance**Time Post-Carrageenan (h)Cellular
Inflammation**

Time Post-Carrageenan (h)C. FMT Correlation to 3 h Paw Thickness
Superhance

AngioSPARK

AngioSense

Paw FL (pmol)

Imaging Acute Paw Edema Induced by
Carrageenan Injection. FMT quantitationof three different vascular imaging agentsthat accumulate in paws of animals with
inflammatory edema induced in the rightfootpad.
A. Paw signal by FMT imaging. Numbers
indicate quantitative pmol per paw.

Paw Thickness (mm)

B. Paw swelling measurement of the edema
response at 3 h and the cellular inflammation
response at 24 h.

D. FRI Paw Fluorescence Measurement
Paw FL (counts/energy)

Superhance

AngioSPARK

AngioSense**#

D. Paw signal by surface planar imaging.
Asterisks indicate statistical significance(# p<0.05, * p<0.01, **p<0.001).

*

Time Post-Carrageenan (h)Figure 13. Comparison to paw swelling responses.
8

C. Correlation of paw thickness and FMT
imaging results.

Conclusions
Superhance, AngioSense and AngioSPARK show clear
differences in physicochemical properties, blood pharmacokinetics, optimal imaging time points, tissue clearance,and overall efficacy in tumor and inflammation imaging.
Table 2 summarizes the findings for these agents in tumor
and paw edema imaging as well as including supportive
summaries from arthritis and intravital microscopy studies.
All three agents provide good tumor definition, with
Superhance affording very early imaging opportunities,
AngioSense generating the greatest signal to background,and AngioSPARK showing long-lasting signal in the tumor

tissue. For inflammatory edema imaging, Superhance shows
the greatest potential in acute paw edema (highest signal tobackground, early time point imaging), whereas AngioSense
and AngioSPARK require longer time for optimal accumulation,
making them more suitable for chronic inflammation models
such as arthritis (data not shown). There are multiple otherapplications currently being explored for these imaging
agents in inflammation models (e.g. asthma, COPD, arthritis,
peritonitis, wound healing), cancer (e.g. tumor xenografts,
orthotopic tumor models, metastasis models), and otherdisease conditions (e.g. graft-versus-host disease, graft
rejection, blood-brain-barrier breakdown, organ failure).

Table 2. Summary information for four applications for Superhance, AngioSense, and AngioSPARK.
Superhance

AngioSense

AngioSPARK

Tumor imaging

+

+++

++

Tumor imaging time3h

24-48 h24-48 hTumor washout

48 h

144 h

>192 hResponse to antiangiogenic agents

nd

+++

nd

Acute edema imaging

+++

+

+

Tissue imaging time

3h

24 h

24 h

Tissue washout

48 h

144 h

>192 hArthritis imaging

nd

+++

+++

Tissue imaging time

nd

24 h

24 h

Tissue washout

nd

144 h

>192 H

Intravital microscopy

++

+++

+++

Optimal imaging time

5-15 min5-60 min

5 min – 3 h9

References
FMT Imaging Technology
P. Mohajerani, A. Adibi, J. Kempner and W. Yared.
Compensation of optical heterogeneity-induced artifacts influorescence molecular tomography: theory and in vivo
validation. J. Biomed. Optics 14:034021 (2009).
Superhance
X. Montet, M. Rajopadhye, and R. Weissleder. An AlbuminActivated Far-Red Fluorochrome for In Vivo Imaging. Chem.
Med. Chem. 1(1):66-69 (2006).
AngioSense
X. Montet, J.L. Figueiredo, H. Alencar, V. Ntziachristos, U.
Mahmood, R. Weissleder. Tomographic fluorescence imagingof tumor vascular volume in mice. Radiology 242(3):751-758(2007).
M. Ackermann, I.M. Carvajal, B.A. Morse, M. Moreta,
S. O’Neil, S. Kossodo, J.D. Peterson, V. Delventhal, H.N.
Marsh, E.S. Furfine, M.A. Konerding. Adnectin CT-322
inhibits tumor growth and affects microvascular architectureand function in Colo205 tumor xenografts. Int. J. Oncol.
38(1):71-80 (2011).

B.A. Binstadt, P.R. Patel, H. Alencar, P.A. Nigrovic, D.M.
Lee, U. Mahmood, R. Weissleder, D. Mathis, C. Benoist.
Particularities of the vasculature can promote the organ
specificity of autoimmune attack. Nature Immunology
7: 284-292 (2006).
J. Haller, D. Hyde, N. Deliolanis, R. de Kleine, M. Niedre, andV. Ntziachristos. Visualization of pulmonary inflammation
using noninvasive fluorescence molecular imaging. J. Appl.
Physiol. 104:795–802 (2008).
AngioSPARK
C. Buono, J.J. Anzinger, M. Amar, and H.S. Kruth.
Fluorescent pegylated nanoparticles demonstrate fluid-phasepinocytosis by macrophages in mouse atherosclerotic lesions.
J. Clin. Invest. 119(5): 1373-1381 (2009).
S.S. Yoon, L. Stangenberg, Y.J. Lee, C. Rothrock, J.M.
Dreyfuss, K.H. Baek, P.R. Waterman, G.P. Nielsen, R.
Weissleder, U. Mahmood, P.J. Park, T. Jacks, R.D. Dodd,
C.J. Fisher, S. Ryeom, and D.G. Kirsch. Efficacy of sunitinib
and radiotherapy in genetically engineered mouse modelof soft-tissue sarcoma. Int . J. Radiat. Oncol. Biol. Phys.
74(4):1207-1216 (2009).

PerkinElmer, Inc.
940 Winter Street
Waltham, MA 02451 USA
P: (800) 762-4000 or(+1) 203-925-4602
www.perkinelmer.com

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs
Copyright ©2011, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.
009731_01